What is the dosage of dapostat? Does it need to be taken for a long time?

Daprodustat is an oral hemoglobin production stimulator (HIF-PH inhibitor) mainly used to treat anemia caused by chronic kidney disease (CKD). It mimics a hypoxic environment by inhibiting hypoxia-inducible factor (HIF)-proline hydroxylase (HIF-PH), thereby increasing the production of endogenous erythropoietin (EPO) and promoting erythropoiesis.

The specific dosage of daprostat depends on the patient's renal function status and response to treatment. For adult patients who have not received erythropoiesis stimulating agents and whose pre-treatment hemoglobin level is <9g/dL, the starting dose of daprostat is 4 mg once daily; the hemoglobin level is ≥9 to ≤10g/dL, the starting dose is once daily2mg; for patients with hemoglobin level >10g/dL, the starting dose is once daily1mg. The maximum recommended dose of daplestat is 24 mg once daily. In general, patients' hemoglobin levels should be monitored and the daplestat dose adjusted as needed, with a common target hemoglobin range of 10-11 g/dL. During treatment with daprostat, doctors will flexibly adjust the medication regimen based on the patient's clinical manifestations and laboratory indicators.

When dapostat is used to treat anemia caused by chronic kidney disease, it usually needs to be taken long-term until kidney function is controlled or returns to normal. In patients with chronic kidney disease, anemia often requires long-term treatment due to long-term decline in renal function, resulting in insufficient secretion of endogenous erythropoietin. Daprostat reduces anemia symptoms by promoting red blood cell production, but discontinuation of the drug may cause anemia to recur. Therefore, in these patients, daplestat usually requires continued use, especially if renal function continues to decline.

When using daprostat, patients need to regularly monitor hemoglobin levels and other related laboratory indicators (such as serum iron, transferrin saturation, etc.) to avoid related complications caused by too high or too low hemoglobin levels. At the same time, daprostat may interact with other drugs. Patients should inform their doctors about all the drugs they are taking so that appropriate adjustments can be made.

Reference materials:https://en.wikipedia.org/wiki/Daprodustat